Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...

Announcing a new publication for Acta Materia Medica journal. Complex biological mechanisms and unidentified therapeutic targets for amyotrophic lateral sclerosis (ALS) significantly hinder the develo ...

Alchemab Therapeutics (Alchemab), a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces it has entered a ...

When he was 25, he learned that he had multiple sclerosis. He coped with the disease throughout a long career at several ...

Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications ...

People who died with sporadic Creutzfeldt-Jakob disease were more likely to have been prescribed antidepressants before ...

Biopharma innovator Alchemab Therapeutics, whose labs are in Cambridge UK, is collaborating with multinational pharma giant ...

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the ...

The UK biopharma company Alchemab Therapeutics announced today that it has joined forces with Eli Lilly to discover, develop, ...

Richard M. Cohen, an outspoken and award-winning television news producer whose career was ultimately derailed by the ...

This content is sponsored by Mitsubishi Tanabe Pharma America, Inc. (MTPA) and is intended for US audiences only. Any other ...

A research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and link HD with other neurodegenerative disorders such as ...